Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by McGuire Investment Group LLC

McGuire Investment Group LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 32,432 shares of the medical research company’s stock after acquiring an additional 79 shares during the quarter. Thermo Fisher Scientific makes up approximately 2.4% of McGuire Investment Group LLC’s holdings, making the stock its 14th biggest holding. McGuire Investment Group LLC’s holdings in Thermo Fisher Scientific were worth $16,872,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in TMO. AQR Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 18.1% in the 2nd quarter. AQR Capital Management LLC now owns 98,152 shares of the medical research company’s stock valued at $54,278,000 after purchasing an additional 15,009 shares during the last quarter. Daymark Wealth Partners LLC raised its stake in shares of Thermo Fisher Scientific by 24.5% in the 2nd quarter. Daymark Wealth Partners LLC now owns 619 shares of the medical research company’s stock valued at $342,000 after acquiring an additional 122 shares during the period. MBB Public Markets I LLC raised its stake in shares of Thermo Fisher Scientific by 767.0% in the 2nd quarter. MBB Public Markets I LLC now owns 29,278 shares of the medical research company’s stock valued at $16,191,000 after acquiring an additional 25,901 shares during the period. Lummis Asset Management LP raised its stake in shares of Thermo Fisher Scientific by 1.2% in the 2nd quarter. Lummis Asset Management LP now owns 3,030 shares of the medical research company’s stock valued at $1,676,000 after acquiring an additional 37 shares during the period. Finally, Lighthouse Investment Partners LLC raised its stake in shares of Thermo Fisher Scientific by 91.3% in the 2nd quarter. Lighthouse Investment Partners LLC now owns 10,892 shares of the medical research company’s stock valued at $6,023,000 after acquiring an additional 5,199 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on TMO shares. Royal Bank of Canada cut their target price on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Bernstein Bank raised their target price on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research note on Tuesday, October 22nd. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target on the stock in a research note on Friday, January 10th. Bank of America dropped their price target on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Finally, Redburn Atlantic began coverage on shares of Thermo Fisher Scientific in a research note on Monday, October 14th. They set a “buy” rating and a $680.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $648.95.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $558.12, for a total transaction of $5,581,200.00. Following the completion of the transaction, the chief executive officer now directly owns 33,608 shares of the company’s stock, valued at $18,757,296.96. The trade was a 22.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 44,850 shares of company stock valued at $24,666,097 in the last ninety days. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.1 %

NYSE TMO opened at $575.21 on Friday. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The company has a 50-day simple moving average of $532.36 and a 200-day simple moving average of $569.05. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The firm has a market capitalization of $220.02 billion, a PE ratio of 36.06, a price-to-earnings-growth ratio of 3.82 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. The business had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company’s quarterly revenue was up .2% on a year-over-year basis. During the same period in the previous year, the business posted $5.69 EPS. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend was Friday, December 13th. Thermo Fisher Scientific’s payout ratio is 9.78%.

Thermo Fisher Scientific declared that its board has initiated a share repurchase plan on Friday, November 15th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.